CA Patent

CA2435730A1 — Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions

Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2002-09-06 · 24y expired

What this patent protects

The invention relates to substituted xanthines of general formula (I) wherei n R1 - R4 are defined as cited in claim 1, the tautomers, stereoisomers, mixtures, prodrugs and salts thereof which exhibit valuable pharmacological properties, particularly an inhibitory effect on the a…

USPTO Abstract

The invention relates to substituted xanthines of general formula (I) wherei n R1 - R4 are defined as cited in claim 1, the tautomers, stereoisomers, mixtures, prodrugs and salts thereof which exhibit valuable pharmacological properties, particularly an inhibitory effect on the activity of the dipeptidylpeptidase-IV enzyme.

Drugs covered by this patent

Patent Metadata

Patent number
CA2435730A1
Jurisdiction
CA
Classification
—
Expires
2002-09-06
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.